1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
[2]
2. Chu DK, Jimenez-Saiz R, Verschoor CP, et al. Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo. J Exp Med, 2014, 211(8): 1657-1672.
[3]
3. McDonald CF. Eosinophil biology in COPD. N Engl J Med, 2017, 377(17): 1680-1682.
[4]
4. Diny NL, Rose NR, ？iháková D. Eosinophils in autoimmune diseases. Front Immunol, 2017, 8: 484.
[5]
5. Percopo CM, Dyer KD, Ochkur SI, et al. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood, 2014, 123(5): 743-752.
[6]
6. Linch SN, Kelly AM, Danielson ET, et al. Mouse eosinophils possess potent antibacterial properties in vivo. Infect Immun, 2009, 77(11): 4976-4982.
[7]
7. Taylor JMG, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res, 2008, 14(19): 5977-5983.
[8]
8. Jameson JL, Longo DL. Precision medicine--personalized, problematic, and promising. N Engl J Med, 2015, 372(23): 2229-2234.
[9]
9. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA, 1999, 282(8): 771-778.
[10]
10. Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med, 2015, 3(2): 120-130.
[11]
11. Sin DD, Pahlavan PS, Man SF. Surfactant protein D: a lung specific biomarker in COPD?. Ther Adv Respir Dis, 2008, 2(2): 65-74.
[12]
12. Obeidat M, Li X, Burgess S, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J, 2017, 50(5): 1700657.
[13]
13. Zhu J, Bandi V, Qiu SY, et al. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest, 2012, 142(2): 347-357.
[14]
14. Ikeda G, Miyahara N, Koga H, et al. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Resp Cell Mol, 2014, 50(1): 18-29.
[15]
15. Benam KH, K？nigshoff M, Eickelberg O. Breaking the in vitro barrier in respiratory medicine. Engineered microphysiological systems for chronic obstructive pulmonary disease and beyond. Am J Respir Crit Care Med, 2018, 197(7): 869-875.
[16]
16. Hollander Z, DeMarco ML, Sadatsafavi M, et al. Biomarker development in COPD moving from P-values to products to impact patient care. Chest, 2017, 151(2): 455-467.
[17]
17. Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
[18]
18. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
[19]
19. Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med, 2017, 195(9): 1189-1197.
[20]
20. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet, 2018, 391(10125): 1076-1084.
[21]
21. Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J, 2017, 50(1): 1700761.
[22]
22. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6): 1697-1700.
[23]
23. Hospers JJ, Schouten JP, Weiss ST, et al. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology, 2000, 3(3): 261-268.
[24]
24. Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med, 2016, 193(9): 965-974.
[25]
25. Kerkhof M, Freeman D, Jones R, et al. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2439-2450.
[26]
26. Landis S, Suruki R, Maskell J, et al. Demographic and clinical characteristics of COPD patients at different blood eosinophil levels in the UK Clinical Practice Research Datalink. COPD, 2018, 15(2): 177-184.
[27]
27. Southworth T, Beech G, Foden P, et al. The reproducibility of COPD blood eosinophil counts. Eur Respir J, 2018, 52(1): 1800427.
[28]
28. Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med, 2018, 138: 21-31.
[29]
29. Serafino-Agrusa L, Scichilone N, Spatafora M, et al. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: a case-control study. Pulm Pharmacol Ther, 2016, 37: 89-94.
[30]
30. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest, 2016, 150(2): 320-328.
[31]
31. Riesbeck K. Inhaled corticosteroids in chronic obstructive pulmonary disease. A two-edged sword. Am J Respir Crit Care Med, 2016, 194(10): 1177-1178.
[32]
32. Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J, 2016, 47(5): 1374-1382.
[33]
33. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014, 371(14): 1285-1294.
[34]
34. Bafadhel M, Davies L, Calverley PMA, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J, 2014, 44(3): 789-791.
[35]
35. Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest, 2017, 151(2): 366-373.
[36]
36. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax, 2016, 71(2): 118-125.
[37]
37. Holland M, Alkhalil M, Chandromouli S, et al. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology, 2010, 15(1): 165-167.
[38]
38. Steer J, Gibson J, Bourke SC. The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax, 2012, 67(11): 970-976.
[39]
39. Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD Severity: an analysis of the SPIROMICS cohort. Lancet Respir Med, 2017, 5(12): 956-967.
[40]
40. Tsiligianni I, Kaplan AG. Are blood eosinophils a prime-time biomarker for COPD management decisions?. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1889-1891.
[41]
41. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker?. Lancet Respir Med, 2017, 5(9): 747-759.
[42]
42. Suzuki M, Makita H, Konno S, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease: An analysis from the Hokkaido COPD cohort study. Am J Respir Crit Care Med, 2016, 194(11): 1358-1365.
[43]
43. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med, 2018, 6(2): 117-126.
[44]
44. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ, 2000, 320(7245): 1297-1303.
[45]
45. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med, 2008, 177(1): 19-26.
[46]
46. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356(8): 775-789.
[47]
47. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, 2016, 387(10030): 1817-1826.
[48]
48. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ, 2013, 346: f3306.
[49]
49. Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med, 2016, 4(9): 731-741.
[50]
50. Vedel-Krogh S, Nordestgaard BG, Lange P, et al. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. Eur Respir J, 2018, 51(5): 1800120.
[51]
51. Roche N, Zysman M, Burgel PR. Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respir Med, 2018, 6(2): 78-80.
[52]
52. Landis SH, Suruki R, Hilton E, et al. Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. COPD, 2017, 14(4): 382-388.
[53]
53. Miller BE, Tal-Singer R, Rennard SI, et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med, 2016, 193(6): 607-613.
